Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into ...


Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025  BROOMFIELD, Colo., Feb.  05, 2026  (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 and an expected public disclosure of early interim results in Q4 of 2026.  “Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” said Jeff Thramann, Executive Chairman of Aclarion. “With cash runway into 2028 and a clean capital structure, we are fully funded to deliver this important clinical milestone. Our focus is on ensuring that the value created by our early data accrues directly to our existing shareholders as we continue advancing a technology that provides physicians with objective biochemical insights to support better decision-making for patients suffering from chronic low back pain.”  The company highlighted its strengthened financial position. Following recent financings, the company reiterated it now has a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital. To reinforce this commitment to shareholder alignment, Aclarion no longer has an ATM in place and its ELOC expired at the end of 2025. The Company currently has 2,882,371 shares outstanding on a fully diluted basis and will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results.  Aclarion also emphasized its position as part of a new generation of software-native MedTech innovators that, unlike traditional device companies, deliver its solution entirely through the cloud. This enables software-level gross margins, rapid scalability, and continuous algorithmic improvement without manufacturing or inventory constraints.  In 2026, the company will be executing a structured investor-awareness strategy focused on institutional healthcare investors, physician-led clinical education, and increased visibility in financial and medical media.  The full 2026 Shareholder Letter is available on the company’s website at: https://investors.aclarion.com/news  For more News from Aclarion, please visit: Latest News  To find a Nociscan center, view our site map here.  For more information on Nociscan, please email: info@aclarion.com  About Aclarion, Inc.  Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.  Forward Looking Statements  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and an expected public disclosure of early interim results in Q4 of 2026, having a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital, the Company will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.   Investor Contacts:  Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com  Media Contacts:  Jessica Starmanmedia@elev8newmedia.com  
            

ACON

Aclarion Publishes 2026 Shareholder Letter from the Chairman

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Aclarion, Inc. projects no capital raises until after the CLARITY trial&#039;s initial data readout in Q3 2026, supported by a cash runway into 2028. The focus on shareholder value resonates amidst advancements in their Nociscan technology aimed at chronic low back pain management. This positions ACON favorably for potential growth as trial results are anticipated.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Aclarion plans no capital raises before CLARITY trial data release.</li><li>Cash runway extends into 2028, ensuring operational viability.</li><li>Shareholder emphasis on aligning value creation and existing investors.</li><li>Company to release CLARITY trial readout in Q3 2026.</li><li>Nociscan technology leverages AI for chronic low back pain management.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Aclarion, Inc. (ACON)</strong>: Favorable positioning ahead of the CLARITY trial readout.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it discusses Aclarion&#039;s clinical and financial strategies. With anticipated trial results and a strong financial footing, the company is set to enhance its market position in MedTech, focusing on innovative solutions for chronic pain management.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming CLARITY trial results could significantly influence ACON&#039;s stock price.</li><li>No capital raise until after trial data could boost investor confidence.</li><li>Strengthened cash position ensures operational stability leading to potential growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Cash runway extends into 2028, ensuring operational capabilities.</li><li>No new ATM or ELOC planned until post-CLARITY results.</li><li>Initial CLARITY trial readout anticipated at the end of Q3 2026.</li><li>2,882,371 shares outstanding on a fully diluted basis.</li><li>Nociscan is a noninvasive SaaS platform aimed at chronic pain.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy ACON ahead of CLARITY trial results expected in Q3 2026.</p>
  </section>
</section>


<article>
    <header>
        <h1>Aclarion Releases 2026 Shareholder Letter Highlighting Key Developments</h1>
    </header>
    <section>
        <p>BROOMFIELD, Colo., Feb. 5, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company focused on chronic low back pain treatment, has announced the publication of its 2026 Shareholder Letter from the Chairman. This letter outlines the company's strategic clinical, financial, and operational goals as it approaches critical milestones in its clinical trial programs.</p>
    </section>
    <section>
        <h2>Strong Financial Position and Future Directions</h2>
        <p>In the letter, Jeff Thramann, Executive Chairman of Aclarion, stressed the company’s robust financial standing. “Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” he stated. The company's cash runway extends to 2028, allowing it to advance its clinical initiatives without the need for additional capital raises.</p>
        <p>Key financial highlights include:</p>
        <ul>
            <li>Cash runway extended into 2028</li>
            <li>No active At-the-Market (ATM) facility or Equity Line of Credit (ELOC); ATM terminated early 2025</li>
            <li>ELOC expired on December 31, 2025</li>
            <li>2,882,371 shares outstanding on a fully diluted basis</li>
        </ul>
    </section>
    <section>
        <h2>Advancements in the CLARITY Trial</h2>
        <p>Aclarion is moving towards an anticipated initial internal readout of its <strong>300-patient CLARITY trial</strong> at the end of Q3 2026. Public disclosure of the early interim results is expected in Q4 2026. This trial is essential for evaluating the effectiveness of Aclarion's innovative Nociscan technology, which employs biomarkers and augmented intelligence for diagnosing low back pain.</p>
    </section>
    <section>
        <h2>Innovative Approach in Healthcare Technology</h2>
        <p>Aclarion's software-native model distinguishes it from traditional medical device companies by enabling solutions that operate entirely through the cloud. This approach fosters:</p>
        <ul>
            <li>High gross margins</li>
            <li>Rapid scalability</li>
            <li>Continuous improvements in algorithms without the limitations of manufacturing</li>
        </ul>
        <p>The company aims to raise awareness among institutional healthcare investors and enhance education for physicians, while increasing visibility in both financial and medical media.</p>
    </section>
    <section>
        <h2>About Aclarion, Inc.</h2>
        <p>Aclarion, Inc. is dedicated to transforming chronic low back pain diagnosis and treatment through its Nociscan platform. This cutting-edge solution utilizes <strong>Magnetic Resonance Spectroscopy (MRS)</strong> to provide insights that help differentiate between painful and non-painful lumbar discs. By leveraging advanced signal processing techniques and augmented intelligence, Nociscan enhances clinical treatment strategies for physicians.</p>
        <p>For further information, visit <a href="https://www.aclarion.com">Aclarion's website</a>.</p>
    </section>
    <footer>
        <p>For the full 2026 Shareholder Letter, please visit the company’s investor relations page at: <a href="https://investors.aclarion.com/news">Aclarion Investors</a>.</p>
    </footer>
</article>

Aclarion, Inc. projects no capital raises until after the CLARITY trial's initial data readout in Q3 2026, supported by a cash runway into 2028. The focus on shareholder value resonates amidst advancements in their Nociscan technology aimed at chronic low back pain management. This positions ACON favorably for potential growth as trial results are anticipated.

Aclarion Publishes 2026 Shareholder Letter from the Chairman

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News